Getting started with CRISPR whole genome screening has never been easier with the NEW Dharmacon All-in-one CRISPR platform.
Arrayed siRNA screens are a powerful tool to look at very precise perturbations in cellular pathways.
Overview of HAP1 cells, their origins, and how we produce knockouts in these cell lines to see how they can assist in your research.
T-cell receptors (TCRs) are crucial components of T cell immunity, enabling the detection and subsequent elimination of abnormal, cancerous and infected cells. Dysfunctional T cell receptor signaling can lead to various immune deficiency or autoimmune diseases. In cancer treatment the study and modification of T cell receptor signaling is important for CAR-T cell therapy as well as modulation of the tumor microenvironment (TME). Modulating T cell activation can be important to avoid rejection of organ or stem cell transplants by the immune response.
Cancer is often characterized by dysregulation in cellular pathways and the checkpoints which control cell proliferation, growth, differentiation, and apoptosis. Within the genome there are two types of genes which carefully control cell proliferation and cell death, which are often the driving force behind oncogenesis.
Revvity’s Dharmacon™ CRISPR portfolio expands with validated CRISPR guide RNAs for complex but critical gene targets, as well as DNA cutting controls for screen normalization in sensitive assays.
3D culturing is a valuable and increasingly popular cell culture technique. This model recapitulates some physiological characteristics of tissues and tumors driven by cell-cell and cell-matrix contacts, circumventing the need for in vivo experiments in some cases.
mTOR, the mechanistic target of rapamycin, sits at the center of a signaling network that coordinates cell growth based on environmental cues and plays an integral role in both cellular and organismal physiology.
The Role of Revvity’s Cell Line in Supporting Wellcome Sanger Institute's genome variant exploration
A blog article demonstrating how Revvity and Wellcome Sanger Institute partnered to generate a HAP1 LIG4(-) Cas9(+) cell line in support of the Atlas of Variant Effects (AVE) alliance.
Read about Celonic's decision to partner with Revvity to leverage the CHOSOURCE™ expression platform for all their antibody and complex molecular development and manufacturing.